Agoracom Blog Home

Posts Tagged ‘pharma’

Empower Clinics Emerges: Unveiling Significant Growth and a Visionary Strategy to Reinvigorate Investor Confidence

Posted by Paul Nanuwa at 3:12 PM on Thursday, April 11th, 2024

As the clinical trials market propels towards an estimated value of USD 887.0 Billion by 2032, Empower Clinics stands at the forefront of harnessing these burgeoning opportunities. Amidst the industry’s dynamic landscape, Empower Clinics is strategically positioned to leverage its expertise and drive innovation in medical research and patient-centric initiatives.

Industry Outlook and Empower Clinics’ Trajectory

The clinical trials industry is witnessing unprecedented growth fueled by escalating demand for innovative therapies and treatments. Empower Clinics is poised to navigate this trajectory with precision, capitalizing on emerging trends and technological advancements to drive transformative change. As the industry evolves, Empower Clinics remains steadfast in its commitment to advancing medical research and delivering impactful solutions.

Voices of Authority

Industry leaders echo Empower Clinics’ strategic vision, recognizing the company’s pivotal role in shaping the future of clinical trials. With a focus on collaboration and innovation, Empower Clinics is poised to drive meaningful advancements that enhance patient outcomes and revolutionize healthcare delivery.

Empower Clinics’ FLASH Highlights

Empower Clinics is a healthcare company with a growing research and clinical trials division that is currently achieving early success in the Dallas and Los Angeles markets. It has already been awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company and the company has grown their active sites from 2 in the fall to 6 at present. Principal Investigators have increased from 6 to 14 with an active pipeline in motion.  That foundation of doctors and medical offices opens the door to potential major contract wins from pharmaceutical companies that need speed and smarts from partners like Empower to get their clinical trials completed.

Real-world Relevance

Empower Clinics’ impact extends beyond the laboratory, translating into tangible benefits for patients and stakeholders alike. By championing patient-centric approaches and leveraging advanced technologies, Empower Clinics is at the forefront of delivering transformative healthcare solutions that address pressing medical challenges.

Looking Ahead with Empower Clinics

As the clinical trials industry continues to evolve, Empower Clinics remains focused on its mission to drive innovation and improve patient outcomes. With a forward-thinking approach and a dedication to excellence, Empower Clinics is poised to unlock new opportunities and redefine the future of medical research and patient care.

Conclusion

In a landscape defined by unprecedented growth and innovation, Empower Clinics emerges as a leader in the clinical trials arena. As the industry continues to evolve, Empower Clinics stands ready to lead the charge towards a brighter, more innovative future.

YOUR NEXT STEPS

Visit $EPW HUB On AGORACOM: https://agoracom.com/ir/EmpowerClinics
Visit $EPW 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/EmpowerClinics/profile
Visit $EPW Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/EmpowerClinics/forums/discussion

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit https://agoracom.com/terms-and-conditions

 

Empower Clinics Emerges from Stealth Mode: A Game-Changer in Healthcare Innovation

Posted by Paul Nanuwa at 3:49 PM on Monday, April 8th, 2024

Small Cap Clinical Trial Company Sets Stage for Significant Growth

Empower Clinics, a burgeoning force in the healthcare sector, has stepped out of regulatory-mandated stealth mode with a robust growth trajectory and an ambitious plan to restore shareholder value. Led by CEO Steven McAuley, the company is poised for substantial expansion in its research and clinical trials division, marking a pivotal moment in its journey towards industry prominence.

Unveiling the Vision

Empower Clinics is not just another player in the healthcare landscape; it’s a company with a grand vision and a strategic roadmap to revolutionize clinical trials. As it emerges from stealth mode, Empower brings to the forefront a compelling narrative of growth and innovation. With a focus on research and clinical trials, the company has swiftly garnered attention for its early successes in key markets such as Dallas and Los Angeles including already being awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company.

Foundational Growth and Promising Prospects

Under McAuley’s leadership, Empower has made significant strides in expanding its operational footprint. From just two active sites in the fall, the company has scaled up to six active sites today. Moreover, the number of Principal Investigators has more than doubled, from six to fourteen. This exponential growth not only underscores Empower’s commitment to excellence but also sets the stage for potential contract wins from global pharmaceutical giants.

Seizing Opportunities in a Booming Market

Empower Clinics’ timing couldn’t be more opportune. With the global Clinical Trials Market projected to reach USD 92.45 billion by 2030, fueled by the burgeoning pharmaceutical, biotechnology, and medical device sectors, Empower is primed to capitalize on this burgeoning market. As demographics shift and medical research advances, the company stands at the forefront of innovation, poised to play a pivotal role in shaping the future of healthcare.

Insightful Interview: A Glimpse into Empower’s Strategy

In a compelling interview with AGORACOM, CEO Steven McAuley provided invaluable insights into Empower’s growth trajectory and strategic imperatives. From navigating regulatory challenges to positioning the company for sustainable growth, McAuley’s vision and leadership shine through, offering shareholders and investors a glimpse into the company’s promising future.

Empower Clinics: A Signal of Hope in Healthcare Innovation

As Empower Clinics emerges from stealth mode, it ushers in a new era of innovation and growth in the healthcare sector. With a steadfast commitment to excellence, a robust foundation of operational success, and a visionary leadership team at the helm, the company is well-positioned to unlock tremendous value for shareholders and stakeholders alike.

Conclusion: Charting a Path to Success

Empower Clinics’ journey from stealth mode to growth mode signifies a significant milestone in its evolution as a player in the healthcare industry. With a compelling business model, a strategic focus on research and clinical trials, and a deep commitment to driving shareholder value, Empower is poised to redefine the future of healthcare innovation. As investors and stakeholders alike rally behind the company’s vision, the future looks brighter than ever for Empower Clinics and its pioneering approach to healthcare transformation.

YOUR NEXT STEPS

Visit $EPW HUB On AGORACOM: https://agoracom.com/ir/EmpowerClinics
Visit $EPW 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/EmpowerClinics/profile
Visit $EPW Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/EmpowerClinics/forums/discussion

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit https://agoracom.com/terms-and-conditions

VIDEO – Valeo Pharma (VPH: CSE) (VPHIF: OTCQB) Hits Record Annual Revenues Of $13.6 MILLION … Targeting $150 MILLION By 2025

Posted by AGORACOM-JC at 7:30 PM on Sunday, March 6th, 2022
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.    

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.     

2021 HIGHLIGHTS:

  • $13.6 MILLION              Record Annual Revenues Up 81% Over 2020
  • $9.1 MILLION                Record 2nd Half Revenues
  • $4 MILLION                   Record Annual Gross Profit Up 186% over 2020
  • $43 MILLION                 Record Financing Through 2021 / Subsequent To Year End 

If you think these numbers are impressive, consider the fact that 3 important factors to their business were only partially launched in fiscal 2021, namely:

●       Each of their transformational products were staggered released, now fully released

●       Insurance & Government reimbursement approvals were staggered, now nearly 100%

●       Corporate Structuring related to staffing and distribution was ramping, now 100%

$150 MILLION REVENUE TARGET BY 2025

Despite the ramp up and staggered milestones, this translated into $9.1M in second half revenue for $VPH, which we would easily extrapolate at 150% – 200% for all of 2022 or ~ $23M – $27M in revenue … but that is just our own back of the napkin math with imperfect information.

If you want to hear it straight from the horses’ mouth $VPH believes it can achieve $150M in revenue by 2025.

Commenting on the fourth quarter and record year-end 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer stated:

“As expected, the significant increase in Q4-2021 revenues and record annual revenues resulted mainly from the addition of the new products launched during the year. Valeo is now very well positioned to leverage its new corporate and commercial infrastructure to capitalize on the market potential of its existing product portfolio,”

 Sit back, relax and watch this powerful interview with CEO Steve Saviuk.

VIDEO – Valeo Pharma Immune Booster Now Available In ~300 Stores Under Loblaws Banner, Another Step Closer to 2025 Revenue Target of $160M

Posted by AGORACOM-JC at 1:40 PM on Thursday, January 6th, 2022
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.    

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.     

The company released stellar a Q3 with the following highlights:    

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

But wait, there’s more…

The company announced that Hesperco™ Is Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted For Publication.

  • Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
    • Loblaws
    • Dominion,
    • Zehrs,
    • Fortinio’s,
    • Your Independent Grocer and Superstore

Steve Saviuk , CEO commented,

We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”

But wait, there’s more…

The company Closed Previously Announced Upsized $15 Million Bought Deal Private Placement And Concurrent $10 Million Private Placement with Investissement Québec.

Now sit back, relax and watch this powerful interview with Valeo Pharma.

Valeo Pharma $VPH $VPHIF Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:44 AM on Wednesday, April 14th, 2021
  • Announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000
  • Valeo insiders participate for $2.6 million

MONTREAL , April 14, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000 (the “Offering”).

Each Debenture Unit will consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a “Debenture”) and 200 Class “A” share purchase warrants (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Class “A” Share of the Company (each, a “Share”) at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the “Closing Date”). The Debentures will mature at the latest 9 months after the closing and will bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears.

“We are appreciative of the continued support from insiders and investors close to the Company  in this placement”, said Steve Saviuk , Valeo’s Chief Executive Officer. “This financing will strengthen our balance sheet at a time of three important product launches for Valeo, Enerzair® Breezhaler®, Atectura® Breezhaler® and Redesca™. Commercialized through two distinct sales forces, these products are key drivers to our growth over the coming years”.

The net proceeds of the Offering will be used for working capital and general corporate purposes.

Closing of the Private Placement is expected to occur on or about April 23, 2021 and is subject to regulatory approval including that of the CSE. The Company may pay finder’s fees on the non-insider portion of the Private Placement, in compliance with applicable securities laws. All securities issued in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.

The issuance of Convertible Debentures to the insiders will be considered related party transactions within the meaning of Multilateral Instrument 61-101 (“MI 61-101”). The Company intends to rely on the exemptions from the requirements of MI 61-101 in respect of any Insider Participation.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurology, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

Valeo Pharma $VPH $VPHIF Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP® $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:12 AM on Tuesday, April 6th, 2021
  • Completed its negotiations and entered into a letter of intent (“LOI”) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.

MONTREAL , April 6, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent (“LOI”) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.

“The successful conclusion of negotiations with pCPA is a significant milestone delivered for the Redesca® commercialization program. We can now exchange with the provincial, territories and federal instances to ensure coverage under publicly funded drug plans in Canada “, said Steve Saviuk , Valeo’s CEO.” While most prescriptions of LMWHs are initiated in the hospital, retail pharmacies play an important role in providing continued treatment to patients when they are discharged from hospital. Coverage by publicly funded drug plans are therefor a key component in making treatment available to Canadians”.

Commenting on the pCPA LOI, Frederic Fasano , Valeo’s President and Chief Operating Officer said; “We are particularly pleased to make Redesca ® available soon for Canadian patients and also for hospitals. The team at Valeo have worked tirelessly to ensure a robust supply of Redesca ® especially in the current pandemic conditions where patients suffering from SARS-CoV-2 are undergoing severe coagulopathy with various thromboembolic complications. LMWHs, like Redesca ® are key to prevent and treat those severe COVID-19 related thrombotic events.”

Established in August 2010 , the pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint provincial/territorial/federal negotiations for brand name and generic drugs in Canada to achieve greater value for publicly funded drug programs and patients through the use of the combined negotiating power of participating jurisdictions.

About Redesca®, Redesca HP®

Redesca® is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca® has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/758564-valeo-pharma-completes-negotiations-with-pan-canadian-pharmaceutical-alliance-for-redesca-and-redesca-hp/messages/2310948#message

AGORACOM Small Cap 60: What Gives Valeo Pharma A Competitive Advantage In The $700M CAD / Year Asthma Market? $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:02 PM on Thursday, April 1st, 2021

Valeo Pharma $VPH $VPHIF Reports its First Quarter 2021 Results and Highlights $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 6:40 PM on Wednesday, March 31st, 2021
  • Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies
  • Q1-21 net revenues of $1.9 million , up 11 % vs Q1-20
  • Frederic Fasano appointed as President and Chief Operating Officer
  • Redesca® and Redesca HP® receive Health Canada approval, launching in Q3
  • Hesperco™ capsules at the core of a Montreal Heart Institute’s COVID-19 study

MONTREAL , March 31, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2021 .

“Our first quarter has laid the foundation for a transformational year for Valeo. The commercialization agreement with Novartis Canada positions  Valeo as one of the leading Canadian companies in respirology .  We are excited about the opportunity to enter the growing asthma market with two innovative drugs, Enerzair® Breezhaler® and Atectura® Breezhaler®.  The Canadian asthma market exceeds $700 million annually 1 and is expected to growth at 2-3% per year over the next ten years. We expect combined peak sales of these two new drugs to exceed $100 million annually.”, said Steve Saviuk , Valeo’s CEO. “With the coming launch of Redesca, our low-molecular-weight-heparin biosimilar, and the Montreal Institute of Cardiology’s ongoing Covid-19 clinical trial involving Hesperco capsules, 2021 marks a turning point in Valeo’s history”.

Commenting on the first quarter 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “Our net revenues for the quarter continued to grow and reflected the addition of several products during the latter part of our 2020 fiscal year. Our first quarter results were impacted by calendar year-end slowdown of the pharma sector as well as increase in operating expenses to support our growth initiatives. Sales & Marketing expenses increased due to the addition of Redesca’s national key account manager team. Our General & Administrative expenses also increased during the quarter as a result of the addition to the Head Office personnel and increased marketing related expenses. We expect additional investments to be made in 2021 as we prepare ourselves to support the Canadian commercialization of Enerzair® Breezhaler® and Atectura® Breezhaler® already approved by Health Canada and available for sale. We anticipate strong revenue growth in the second quarter of fiscal 2021 and accelerated growth in the coming quarters as a result of these product additions which will derive incremental margins and drive our profitability going forward.

References:

  1. IQVIA CDH June 2020

First Quarter 2021 Financial Results and Highlights

  • Net revenues were $1.9 million for the quarter ended January 31, 2021 compared to $1.7 million for the quarter ended January 31, 2020 . The increase over the previous comparable period is mainly due to the Onstryv revenue growth and the launch of new products such as Ametop, Yondelis and the launch of Sodium Ethacrynate in the U.S. ;
  • Net loss of $1.7 million for the quarter ended January 31, 2021 compared to $1.1 million for the quarter ended January 31, 2020 . The increase in net loss is a result of the increase in Sales & Marketing and General & Administrative expenses required to position Valeo for solid revenue growth in 2021; and
  • Adjusted EBITDA loss of $1.1 million for the quarter ended January 31, 2021 compared to $0.9 million for the quarter ended January 31, 2020 .

First Quarter 2021 Business and Product Highlights

  • In January 2021 , the Company received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of Redesca® and Redesca® HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ);
  • In January 2021 , the Company appointed Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer. Mr. Fasano is a seasoned Canadian and international pharma executive having lead pharmaceutical organizations in Europe and Canada. His addition augments Valeo’s senior leadership team and support expansion of Valeo’s commercial activities;
  • In December 2020 , the Company announced that its shares were eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company (“DTC”);
  • In December 2020 , the Company received a Notice of Compliance from Health Canada for its Redesca and Redesca HP low molecular weight heparin (“LMWH”) biosimilars; and
  • In November 2020 , the Company received a Notice of Compliance from Health Canada granting market authorization for Amikacin and commenced shipments of Ethacrynate Sodium in the U.S. market.

Subsequent Events

  • In March 2021 , the Company entered into a Commercial and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate); and
  • In February 2021 , the Company announced that Hesperco™ capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”;

Q1 2021 Webcast and Conference Call

Valeo will host a conference call to discuss the first quarter 2021 results and highlights on Thursday April 1, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (5555964).

A live audio webcast of the conference call will be available via:

https://produceredition.webcasts.com/starthere.jsp?ei=1444812&tp_key=929d96e070

Financial Statements and MD&A

Valeo Pharma’s financial statements and Management’s Discussion and Analysis for the three-month ended January 31, 2021 are available on SEDAR at www.sedar.com

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

AGORACOM Small Cap 60: How Big Is Valeo Pharma’s $VPH $VPHIF Commercialization and Supply Agreement With Novartis? $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:04 PM on Wednesday, March 31st, 2021
Valeo Pharma (@valeo_pharma) | Twitter

VIDEO – Valeo Pharma $VPH $VPHIF Enters Commercialization and Supply Agreement With Novartis To Address the $700M/ Year CDN Asthma Medication Market $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:41 PM on Monday, March 29th, 2021

Valeo Pharma Inc . (VPH: CSE) (VPHIF: OTCQB) (VP2: FSE) announced today that it has entered into a Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc.for the Canadian commercialization by Valeo of two asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate),  glycopyrronium (as bromide) and mometasone furoate) 3 and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate).

Under the Agreement, Valeo will be responsible for medical and commercial activities for an initial 8 year period.

How Significant Is This Market?

At present, almost 4 million Canadians are living with asthma a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today’s most advanced therapies. The Canadian market for asthma medication exceeds $700M annually.

What Does The CEO of Valeo say about the deal?

“We are extremely pleased to be partnering with Novartis to launch these two  asthma drugs in the coming weeks. Commercializing Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually,” said Steve Saviuk , CEO of Valeo. “This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.”

Sit Back, relax and watch this powerful interview with Steve Saviuk , CEO of Valeo.